|Videos|May 1, 2023
A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial
Author(s)Toni K. Choueiri, MD, Rohit Gosain, MD
Drs Choueiri and Gosain review study design, patient demographics, and clinical characteristics from the CheckMate 9ER trial, including prior nephrectomy and PD-L1 status.
Advertisement
Advertisement
Related to this article
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
3
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
4
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
5